Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab
Maria Thor, Annemarie F. Shepherd, Isabel R. Preeshagul, Michael Offin, Daphna Y. Gelblum, Abraham J. Wu, Aditya Apte, Charles B. Simone, Matthew D. Hellmann, Andreas Rimner, Jamie E. Chaft, Daniel R. Gomez, Joseph O. Deasy, Narek Shaverdian
Topics & Concepts
DurvalumabMedicineInternal medicineOncologyHazard ratioRadiation therapyLung cancerImmune systemCancerGastroenterologyConfidence intervalImmunologyImmunotherapyNivolumabCancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease PrognosisLung Cancer Diagnosis and Treatment